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Abstract: Protein binding prevents uremic toxins from removal by conventional 
extracorporeal therapies leading to accumulation in maintenance dialysis patients. 
Weakening of the protein binding may enhance the dialytic elimination of these toxins. In 
ultrafiltration and equilibrium dialysis experiments, different measures to modify the 
plasma binding affinity and capacity were tested: (i), increasing the sodium chloride 
(NaCl) concentration to achieve a higher ionic strength; (ii), increasing the temperature; 
and (iii), dilution. The effects on the dissociation constant KD and the protein bound 
fraction of the prototypical uremic toxin indoxyl sulfate (IS) in plasma of healthy and 
uremic individuals were studied. Binding of IS corresponded to one site binding in normal 
plasma. KD increased linearly with the NaCl concentration between 0.15 (KD = 13.2 ± 3.7 µM) 
and 0.75 M (KD = 56.2 ± 2.0 µM). Plasma dilution further reduced the protein bound toxin 
fraction by lowering the protein binding capacity of the plasma. Higher temperatures also 
decreased the protein bound fraction of IS in human plasma. Increasing the NaCl 
concentration was effective to weaken the binding of IS also in uremic plasma: the protein 
bound fraction decreased from 89% ± 3% to 81% ± 3% at 0.15 and 0.75 M NaCl, 
respectively. Dilution and increasing the ionic strength and temperature enhance the free 
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fraction of IS allowing better removal of the substance during dialysis. Applied during 
clinical dialysis, this may have beneficial effects on the long-term outcome of maintenance 
dialysis patients. 
Keywords: kidney disease; uremic toxin; protein binding; ionic strength; hemodialysis 
Abbreviations: Bm: maximal binding capacity; ESRD: end-stage renal disease; IS: indoxyl 
sulfate; KA: association constant; KD: dissociation constant; NaCl: sodium chloride;  
RP-HPLC: reversed-phase high performance liquid chromatography 
 
1. Introduction 
The uremic syndrome is attributed to the accumulation of a large number of compounds, which in 
healthy individuals are excreted by the kidney. These compounds are called uremic retention solutes or 
uremic toxins since they have deleterious effects on the human organism. Indoxyl sulfate (IS, 213 Da) 
is a prototypical protein-bound uremic toxin [1]. In chronic kidney disease, particularly in patients on 
maintenance dialysis, IS is associated with cardiovascular outcome and mortality [2–4].  
Albumin (molecular weight 66.5 kDa) is the most abundant plasma protein with a concentration of 
about 570 µM (38 g/L) [5,6]. It is a carrier protein for many hydrophobic compounds in plasma [6,7]. 
Numerous uremic toxins bind specifically to the Sudlow’s sites I and II of human serum albumin [8], 
thereby, leading to impaired binding of drugs [8,9]. IS binds to the Sudlow’s site II in subdomain IIIA 
with an association constant KA = 9.1 × 10
5
 to 16.1 × 10
5
 M
−1
 (corresponding to a dissociation constant 
KD = 0.6 to 1.1 µM) [10,11]. In principle, the protein binding of uremic toxins is reversible since it is 
mainly driven by electrostatic and/or van der Waals forces [9,12]. Due to its high protein bound 
fraction and high distribution volume resulting in low dialytic clearance [13–20], IS is poorly removed 
by existing extracorporeal renal replacement therapies, such as hemodialysis.  
Several studies have investigated the protein binding of uremic toxins exclusively in albumin 
solution as a surrogate for plasma [10,11,21,22]. Such an approach does not take into account a 
possible competition of different plasma compounds for the limited number of binding sites.  
The present study was performed to quantitatively describe the binding of IS in more physiological 
conditions as in [23], and to apply different experimental settings in order to develop the basis for 
methods which enhance the clearance of protein bound substances during clinical hemodialysis.  
2. Results 
2.1. Binding of IS to Normal Human Plasma at Different Temperature and Ionic Strength 
A rise in temperature from 25 °C to 37 °C significantly reduced the fraction of protein bound IS  
in both 0.15 M NaCl (90% ± 2% to 86% ± 1%, p < 0.05) and 0.61 M NaCl solution (83% ± 2%  
to 77% ± 2%, p < 0.01). 
Mathematical modeling (Equation (2) versus Equation (3)) revealed that, independently of the ionic 
strength, the binding of IS in normal human plasma best fits to a one binding site model. The binding 
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constants of a second binding site in plasma were calculated to be irrelevant. One site-specific binding 
curve (Equation (2)) at 0.15 M and 0.75 M NaCl are presented in Figure 1D,E, respectively. Scatchard 
plots of IS in normal human plasma are shown for 0.15 M and 0.75 M NaCl (Figure 1A,B, 
respectively). Similar results were obtained for 0.30 M and 0.50 M NaCl (data not shown). Binding 
constants calculated from the Scatchard plot (KD = 10.9 ± 2.0, 22.1 ± 6.5, 39.7 ± 11.1 and 54.9 ± 5.9 µM; 
Bm = 228 ± 52, 251 ± 33, 296 ± 54, and 318 ± 54 µM, at 0.15 M, 0.30 M, 0.50 M, and 0.75 M, 
respectively) did not significantly differ from the values obtained from non-linear regression  
using Equation (2). As shown in Figure 2, an increase of the ionic strength highly correlated with  
KD (r² = 0.98; p < 0.05) and the ratio KD/Bm (r² = 0.98; p < 0.01). The maximal binding capacity Bm 
slightly increased with the ionic strength. However, compared to isotonic NaCl concentration, this 
finding was statistically significant only at the highest ionic strength of 0.75 M. Increasing the ionic 
strength resulted in a significant decrease (p < 0.05) of the protein bound fraction from 95% ± 1% at 
0.15 M NaCl to 91% ± 2%, 87% ± 3%, and 84% ± 2% at 0.30 M, 0.50 M, and 0.75 M NaCl, 
respectively, at low toxin-albumin ratio (α = 0.1). The theoretical protein bound fraction for α = 0.1 
was 94% ± 2%, 90% ± 2%, 87% ± 3%, and 84% ± 3% at 0.15 M, 0.30 M, 0.50 M, and 0.75 M, 
respectively. Experimental and theoretical protein bound fractions highly correlated (r² = 0.99; p < 0.0001).  
Figure 1. Scatchard plot of the protein binding of indoxyl sulfate (A–C) and corresponding 
binding curves (D–F) in normal human plasma. Plasma was 1:2 diluted and incubated at 
0.15 M NaCl (A,D) and 0.75 M NaCl (B,E). 1:10-diluted plasma was incubated only at 
0.15 M NaCl (C,F). Each experiment was performed with plasma from three different 
donors (squares: donor 1, triangles: donor 2, crosses: donor 3, and circles: donor 4). 
Indoxyl sulfate bound to one high affinity binding site in normal plasma. Regression 
coefficients r
2
 were: (A) 0.95, 0.98, and 0.96; (B) 0.96, 0.89, and 0.97 for donors 1, 2, and 
3, respectively; (C) 0.94, 0.92 and 0.75 for donors 1, 3 and 4, respectively. Regression 
coefficient r
2
 of the binding curves; (D–F) was always 1.00. 
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Figure 2. Effect of the ionic strength on the dissociation constant KD (solid line) and the 
ratio KD/Bm (dotted line) for indoxyl sulfate in 1:2-diluted plasma. KD and KD/Bm correlate 
with the ionic strength according to KD = 71.2 × NaCl concentration + 5.1 and  
KD/Bm = 0.20 × NaCl concentration + 0.03, respectively. * p < 0.05 versus 0.15 M NaCl. 
 
2.2. Correlation of the Ionic Strength with the Protein Bound Fraction of IS in Uremic Plasma 
With increasing ionic strength, the protein bound fraction of IS decreased significantly in plasma of 
uremic and healthy individuals (Figure 3A,B, respectively). Compared with uremic plasma, the protein 
bound fraction in normal plasma was about 4% higher at 0.15 M and 0.30 M NaCl (p < 0.01). There 
was no significant difference between uremic and IS added healthy plasma regarding the mean total IS 
concentration (69.4 ± 35.5 µM versus 56.7 ± 54.5 µM, respectively). Considering Equation (1) with an 
experimental albumin concentration of 286 µM after 1:2 dilution, i.e., hypothesizing Bm being constant 
at 286 µM, a higher NaCl concentration in uremic plasma correlated with KD for IS (27.3 ± 8.6 µM, 
37.1 ± 10.6 µM, 46.5 ± 16.9 µM, and 55.9 ± 15.3 µM at 0.15 M, 0.30 M, 0.50 M, and 0.75 M NaCl, 
respectively (r² = 0.40; p < 0.0001)). 
Figure 3. Effect of an increased NaCl concentration on the protein bound fraction of 
indoxyl sulfate in uremic (A); n = 15, free and bound native toxin concentrations) and 
healthy (B); n = 18 (3 different donors spiked with 6 different toxin concentrations), free 
and bound toxin concentrations) human plasma. Increasing ionic strength led to lower 
protein bound fractions of indoxyl sulfate in both uremic and normal plasma. * p < 0.05. 
 
2.3. Effect of Dilution and Higher Ionic Strength on Toxin Binding in Human Plasma 
For a given NaCl concentration, 1:2 and 1:10 dilution did not affect the binding affinity KD  
(see Table 1), while the maximal binding capacity Bm was decreased significantly (p < 0.05), being 
equivalent to the albumin concentration (238 ± 90 µM for 1:2 and 48 ± 18 µM for 1:10 dilution). 
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Fitting models (Equation (2) versus Equation (3)) confirmed a single high affinity binding site in 1:10 
diluted human plasma, as also shown by the corresponding Scatchard plot (Figure 1C). Appropriate 
results were obtained for 0.50 M NaCl (data not shown). Binding constants calculated by Scatchard 
plot (KD = 8.5 ± 0.4 and 48.5 ± 6.7 µM; Bm = 55 ± 14 and 124 ± 38 µM, at NaCl 0.15 M and 0.50 M, 
respectively) did not differ from the values obtained by non-linear regression using Equation (2). 
Experimental and theoretical protein bound fractions highly correlated (r² = 0.98; p < 0.0001). 
Table 1. Binding constants KD and Bm and protein bound fraction of indoxyl sulfate in 1:2 
and 1:10-diluted normal human plasma. Abbreviations: [NaCl], sodium chloride 
concentration; α, toxin-protein ratio. Values are mean ± SD (n = 3). Plasma dilution 
modified only Bm and, thus, the ratio KD/Bm. The effects of higher [NaCl] on the protein 
bound fractions of IS, as assessed by Equation (1), are also shown. 
(a)
 p < 0.05 versus 1:2 
dilution; 
(b)
 p < 0.05 versus 0.15 M NaCl; 
(c)
 p < 0.05 versus theoretical bound fraction. 
[NaCl] 
[M] 
Dilution 
factor 
KD  
[µM] 
Bm  
[µM] 
KD/Bm 
Theoretically bound 
fraction α = 0.1  
[%] 
Experimentally 
bound fraction α = 0.1  
[%] 
0.15 1:2 13.4 ± 3.6 261 ± 64 0.05 ± 0.02 94 ± 2 95 ± 2 (c) 
0.50 1:2 40.1 ± 18.4 297 ± 64 0.13 ± 0.05 (b) 87 ± 4 (b) 88 ± 4 (b) 
0.15 1:10 8.9 ± 2.7 59 ± 24 (a) 0.16 ± 0.02 (a) 85 ± 1 (a) 86 ± 3 (a) 
0.50 1:10 44.7 ± 18.3 109 ± 27 (a) 0.41 ± 0.11 (a,b) 70 ± 5 (a,b) 73 ± 6 (a,b) 
3. Discussion 
IS is a prototypical, highly protein bound uremic toxin associated with the morbidity and mortality 
of maintenance dialysis patients [2–4]. In vitro experiments have shown its implication in bone and 
cardiovascular disorders frequently observed in uremic patients. Bone disease is elicited by IS by 
inhibiting osteoclast differentiation and function, and by inducing osteoblast resistance to parathyroid 
hormone [24,25]. Cardiovascular disease is promoted by IS induced oxidative stress, leading to 
inhibition of endothelial cell proliferation and wound repair [26,27]. Although it is a rather small 
compound (213 Da), IS removal by hemodialysis is impaired due to the binding to larger proteins, 
which, in contrast to the free toxin, are prevented from passing dialysis membranes. Therefore, 
releasing IS from its protein binding sites would promise more efficient removal, but would require a 
modification of existent dialysis procedures. To achieve such a goal, investigating the effects of 
clinically applicable methods on protein binding represents an obvious initial approach.  
As demonstrated by equilibrium dialysis in aqueous solution, IS binds to albumin with an affinity 
KD of 0.6 to 1.1 µM [10,11]. The present experiments exploring ultrafiltration, which is closer to 
clinical dialysis, demonstrated that in human plasma at physiological ionic strength and room 
temperature IS is bound to proteins with a higher KD of 13.4 ± 3.6 µM. This much lower affinity for IS 
in plasma may be best explained by the presence of potential competing ligands, such as fatty  
acids, which may alter the binding properties of albumin by occupying the binding site [28].  
A methodological artifact can be excluded because comparable protein bound fractions of IS were 
obtained with both ultrafiltration and equilibrium dialysis. Together with protein adsorption onto the 
semipermeable dialysis membrane [29], ultrafiltration of plasma water leads to an increase of the 
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protein concentration in the retentate and, thus, a shift in the equilibrium. This phenomenon is well 
known from clinical hemodialysis, especially during post-dilution hemodiafiltration, a dialysis 
procedure, which combines excess ultrafiltration of plasma water to diffusion, leading to protein 
concentration within the dialyzer near the membrane surface. The high variability of KD observed in 
the present experiments (Figure 2) reflects the interindividually different concentrations of competing 
ligands, which alter the ability of plasma from different individuals to bind toxins [30–32]. 
In the present experiments a single class of high affinity binding sites were found for IS in plasma. 
This finding was supported by comparing one site and two site specific binding models (Equations (2) 
and (3), respectively). Moreover, no difference was found between the Scatchard plot (i.e., interception 
with X-axis) and non-linear regression (Equation (2)) when calculating Bm. In both cases, Bm was in 
the range of the varying albumin concentrations. As calculation of the ratio of bound and free ligand 
from the Scatchard plot may promote errors in the resulting binding constants, the results obtained by 
non-linear regression were preferred and further reinforced by the information provided from the 
Scatchard plot. In previous publications it was found that IS binds to two binding sites in human serum 
albumin solution (one with high, the other with low affinity) [23,33]. The difference in the number of 
binding sites between plasma and albumin solution according to the results of the present study and the 
literature, respectively, may be best explained by the presence of multiple competitors, such as  
fatty acids, which are absent in purified albumin solution and occupy the low affinity binding site in 
plasma [32,34]. As previous studies have shown that IS binds to Sudlow’s site II of albumin [10,11], it 
must be bound to the same binding site also in plasma. 
Increasing the NaCl concentration from physiological 0.15 M to 0.75 M effectively decreased the 
protein bound fraction of IS in both normal plasma (from 93% ± 3% to 83% ± 4%) and plasma from 
uremic patients (from 89% ± 3% to 81% ± 3%). The lower protein bound fraction in uremic plasma 
can be explained by competition of other uremic toxins, such as p-cresyl sulfate [19], which are not 
present in healthy human plasma, for the albumin-binding site. Supporting this argument, compared to 
IS, the native p-cresyl sulfate concentration in uremic plasma (90 ± 28 µM, data not shown) and its 
protein bound fraction (91% ± 2% at 0.15 M NaCl, data not shown) were in the same range.  
The decrease of the protein bound fraction of IS was associated with a linear increase of KD being  
56.2 ± 2.0 µM at 0.75 M NaCl versus 13.4 ± 3.6 µM at 0.15 M. An increase of the ionic strength may 
result in a modification of electrostatic charges within the binding pocket of albumin and/or a 
modification of the protein conformation interfering with IS binding. As no decrease of Bm at the given 
NaCl concentrations was observed, it can be concluded that electrostatic interactions definitely are 
involved. This result is in agreement with previous findings, which demonstrated that increasing the 
ionic strength to 0.30 M NaCl decreased the binding affinity of serum albumin for both p-cresol and  
p-cresyl sulfate [26]. Furthermore, the same was reported for naproxen [35], a drug known to bind to 
Sudlow’s site II [36]. 
Two to tenfold dilution of plasma also showed to be effective for decreasing the protein bound 
fraction of IS. This effect was additive to that of an increased NaCl concentration and can be explained 
by an increase of KD with rising ionic strength and a decrease of Bm with dilution. Both effects 
cumulate and lead to an increase in the ratio KD/Bm and, a fortiori, to a reduction of the protein bound 
fraction (Figure 4). Clinical and experimental observations support this phenomenon [11,37,38]. Low 
serum albumin concentrations in uremic patients were found to correlate with a higher free fraction of 
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p-cresyl sulfate [29]. The same authors confirmed this finding by testing different bovine serum 
albumin concentrations in vitro [37], supporting the data of the present study, which demonstrated that 
plasma dilution did not influence KD. Weisiger et al. reported that the apparent affinity of human 
serum albumin for bilirubin was inversely proportional to the protein concentration, although, the 
affinity was rather constant for albumin concentrations greater than 100 µM [38]. The binding affinity 
of human serum albumin for dansylsarcosine, a marker ligand of albumin site II, was similar when 
using 40 µM or 200 µM albumin [11]. Thus, it is important to take the protein concentration or plasma 
dilution into consideration when comparing the protein bound fractions from different experiments or 
clinical studies. Therefore, in the present binding inhibition experiments with IS and NaCl in normal 
and uremic plasma, the same plasma dilution always was applied (native plasma was diluted 1:2).  
Figure 4. Theoretical course of the protein bound fraction as a function of KD/Bm for 
different toxin-protein ratios α according to Equation (1). α and KD/Bm were varied  
from 0.01 to 1 mol/mol and from 10
−4
 to 10
2
 mol/mol, respectively. The binding curve 
corresponds to a single high-affinity binding site on protein. 
 
Increasing the temperature from room to body temperature further decreased the protein bound 
fraction of IS in normal human plasma. Thus, our data are in agreement with [23]. Confirming  
Bergé-Lefranc et al., who reported that enhancing the temperature reduced the affinity of human serum 
albumin for both p-cresol and p-cresyl sulfate without changing the protein structure in this 
temperature range [39], this finding is in accordance with the Van’t Hoff equation. Thus, compared to 
body temperature, performing the present experiments at room temperature should have overestimated 
the protein bound fraction and the binding affinity of IS in human plasma. Therefore, the influence of 
increased ionic strength during clinical dialysis (body temperature) should be greater than observed in 
the experiments. Based on the removal of only the free toxin fraction during hemodialysis [21,22], an 
increase of the free fraction of IS in uremic plasma from 11% (0.15 M NaCl) to 19% (0.75 M NaCl) 
should double its plasma clearance. Different modifications of the setup are conceivable, which 
theoretically allow the application of higher ionic strengths in plasma or blood during clinically 
practiced hemodialysis.  
Finally, it was verified for normal plasma if Equation (1) is suited to allow an accurate prediction of 
the experimentally bound fraction of IS from the binding constants independently of the plasma 
dilution. At low toxin concentrations, the protein bound fraction correlated directly with the binding 
affinity KD and the maximal binding capacity Bm and, thus, with the protein concentration [40]. 
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Advantageously reflected by Equation (1), the binding affinity in uremic plasma can be assessed when 
knowing the protein bound fraction, the toxin and the receptor protein concentrations, which all can be 
determined experimentally. As albumin was not measured in the plasma samples, a mean albumin 
concentration of 570 µM, which is in accordance with previous studies in dialysis patients [5,19,41], 
and a Bm equal to the human serum albumin concentration were taken as assumptions for the 
calculations. Equation (1) yielded that increasing the NaCl concentration in uremic plasma from 0.15 M 
to 0.75 M NaCl enhanced KD for IS from 27.3 ± 8.6 µM to 55.9 ± 15.3 µM. This estimated binding 
affinity reflects the apparent affinity of uremic plasma for IS and is similar to that found in normal 
plasma. A methodological artifact was excluded by verifying the stability of albumin during freezing 
of the plasma samples. In three plasma samples, a constant human albumin concentration was 
confirmed before freezing at −20 °C and after thawing (43 ± 6 g/L, p = 0.18). 
To note, performing direct binding studies in native uremic plasma is difficult to interpret because 
of the competition between the multiple protein bound uremic toxins present in plasma and any newly 
added ligand [8–11,30]. Alternatively, free and bound toxin concentrations, and the binding constants 
in plasma from a large number of uremic patients, could be assessed. Drawback of this approach is the 
huge array of required samples and the interindividual variability interfering with accurate calculations.  
Some shortcomings of the present study need to be addressed. The experiments may have been 
confounded by some differences in anticoagulation, which were due to a matter of blood availability. 
Despite the fact that De Smet et al. reported interference of heparin with free p-cresol determination [42], 
an effect of anticoagulation on the protein binding in the present setting must be doubted as the blood 
was heparinized during donation. Thus, equilibrium of fatty acids binding should have been already 
reached upon experimentation. Furthermore, to keep the plasma dilution constant between 
experiments, the amount of PBS with physiological pH was adapted. As plasma is a natural buffer 
solution, this method should not have had a major impact on the pH stability of the samples. Finally, 
different to uremic plasma, normal plasma needed to be spiked with different amounts of IS available 
in form of a potassium salt to verify the effect of increased ionic strength in vitro. With respect to the 
NaCl concentration (at least 150 mM), the increase in ionic strength resulting from the introduced 
potassium (the highest concentration being about 0.15 mM) was negligible. 
In summary, uremic and normal plasma do not differ in terms of the binding affinity for protein 
bound toxins with respect to increased ionic strength as demonstrated using the example of the 
prototypical IS. Furthermore, Equation (1) is a useful tool to describe binding properties of similar 
toxins in normal and uremic plasma. 
4. Experimental Section 
4.1. Modeling of the Protein Bound Toxin Fraction 
Models characterizing the behavior of protein bound solutes during dialysis have been developed 
based on the removal of the unbound toxin fraction from bovine serum albumin solution [21,22]. As 
the binding of uremic toxins, such as IS, follows the law of mass action, it is possible to describe their 
protein bound fraction as a function of the binding constants (KD, and Bm, the maximal binding 
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capacity) and the toxin-protein ratio α = LT/Bm, according to Equation (1), where LT is the total toxin 
concentration (also refer to Figure 1): 
 
(1) 
This equation, reflecting one site specific binding, was adapted [22] by isolating the ratio KD/Bm. For 
details of the calculation refer to the Supplemental Data section, Equation (1).  
4.2. Binding Capacity of Human Plasma at Different Temperature and Ionic Strength 
Experiments using plasma obtained from four different donors by centrifugation of whole blood 
were performed at two different ionic strengths. Firstly, 17.5 mL freshly donated heparinized  
(5 IU/mL) plasma from a single healthy donor was diluted with the same volume of phosphate 
buffered saline pH 7.4 (PBS pH 7.4; Sigma Life Science, Sigma-Aldrich, Steinheim, Germany). 
Secondly, to obtain euvolemic plasma with higher ionic strength, 17.5 mL heparinized plasma was 
mixed with 8.75 mL PBS pH 7.4 and 8.75 mL 2.0 M NaCl (sodium chloride for analysis, Merck, 
Darmstadt, Germany), resulting in 1:2 diluted plasma of 0.61 M NaCl concentration. Both preparations 
were dialyzed (flow rate 2.1 mL/min) at 25 °C and 37 °C against a solution of 150 µM IS (indoxyl 
sulfate potassium salt, Sigma-Aldrich) of corresponding ionic strength (0.15 M and 0.61 M NaCl) using 
a mini-dialyzer with a low-flux dialysis membrane (Cuprophan
®
, cut-off 6 kDa, surface area 125 cm², 
inner and outer compartment each 4.6 mL; Membrana GmbH, Wuppertal, Germany). Samples for the 
measurement of the total toxin concentration by reversed-phase high performance liquid 
chromatography (RP-HPLC) were collected from the plasma and the dialysate compartments of the 
diaylzer when the equilibrium was reached after 1 h. The equilibrium point was determined during a 
prior pilot experiment (data not shown). 
4.3. Binding Affinity of Human Plasma for IS at Different NaCl Concentrations 
Experiments were performed with 0.5 mL citrate-plasma (fresh frozen plasma; Bavarian Red Cross 
Blood Donor Service, Munich, Germany), which was incubated for 30 min at room temperature at 
different NaCl concentrations in PBS pH 7.4 (NaCl concentration: 0.15 M, 0.30 M, 0.50 M, and 0.75 M). 
IS was added to reach a concentration of 8, 15, 23, 30, 90, and 150 µM. After adding IS and NaCl,  
the volume of PBS was adjusted to finally obtain 1:2 diluted plasma. The toxin/albumin ratio was  
kept ≤1.0 mol/mol to avoid non-specific binding. In each sample, the free and total IS concentrations 
were measured by RP-HPLC. Scatchard plots were generated for the free and bound IS concentrations. 
The binding constants KD and Bm were determined by nonlinear regression, comparing the one site 
specific binding model (Equation (2)) with the two sites specific binding model (Equation (3)) by 
means of the ―extra sum-of-squares F test‖ (software GraphPad Prism, version 6.00 for Windows, 
GraphPad Software, La Jolla, CA, USA). 
 
(2) 
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where RL and L are the bound and free toxin concentration, respectively. 
 
(3) 
where ―high‖ and ―low‖ refer to the high and low affinity binding sites, respectively. 
The binding constants KD and Bm were also assessed from Scatchard plots, i.e., by calculating the 
absolute value of the inverse slope and the interception with the X-axis, respectively. 
4.4. Binding Capacity of Uremic Plasma for IS at Different NaCl Concentrations 
After having received approval from the competent institutional review board (ethics committee  
of the University Hospital Würzburg, code AZ 64/12), written informed consent was obtained  
from 15 end-stage renal disease patients on maintenance hemodialysis in a single dialysis center 
(Dialysis center, Elsenfeld, Germany). Blood (7.5 mL) was collected in EDTA-tubes from each patient 
before dialysis. Plasma was obtained by centrifugation (10 min at 2000g) and stored at −30 °C. For the 
binding experiments, 0.5 mL uremic plasma was incubated for 30 min at different NaCl concentration 
(0.15 M, 0.30 M, 0.50 M, and 0.75 M NaCl) in PBS pH 7.4 at room temperature. After adding NaCl, 
the volume of PBS was adjusted to attain 1:2 dilution of the plasma. For each sample, the free and total 
IS concentrations were measured by RP-HPLC. 
4.5. Effect of Plasma Dilution on the Binding Capacity in Vitro 
These experiments were performed in citrate-plasma (fresh frozen plasma; Bavarian Red Cross 
Blood Donor Service) with a final dilution of either 1:2 or 1:10. Plasma (0.5 mL or 0.1 mL) was 
diluted with PBS, NaCl solution and IS solution to reach a final NaCl concentration of 0.15 M and 
0.50 M, respectively, and a final volume of 1.0 mL. To 1:2-diluted samples IS was added to obtain the 
same concentrations as described above. 1:10-diluted samples contained only one fifth of the IS 
concentrations targeted in 1:2 diluted plasma. The samples were incubated for 30 min at room 
temperature, further analyzed by RP-HPLC, and the binding constants KD and Bm were determined as 
previously described.  
4.6. RP-HPLC Method 
To determine the total IS concentration, all samples were diluted 1:5 with PBS pH 7.4 in  
glass tubes. Then, protein was precipitated at 95 °C for 30 min and the tubes were centrifuged  
(5 min at 10,000g). The clear supernatant was ultrafiltered (30 kDa filter-units, VWR centrifugal filter, 
VWR International, Darmstadt, Germany) to remove remaining larger proteins and the free IS 
concentration was determined in the resulting filtrate. The obtained clear filtrates were subjected to 
RP-HPLC (Gynkothek pump M480, auto-sampler Gynkothek Gina 50, on-line degasser ERC-3315a 
and column oven Gynkothek STH; Gynkothek/Dionex, Idstein, Germany). The IS concentration was 
measured using a C18 column (ProntoSIL Hypersorb ODS 3.0 µm, 250 × 4.6mm, Bischoff 
Chromatography, Leonberg, Germany) and fluorescence detection (spectrofluorometric detector  
RF-551, Shimadzu, Kyoto, Japan; λex = 280 nm/λem = 340 nm). The samples were eluted at 30 °C 
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using a gradient from 15% to 25% v/v of solvent A (50mM NH4COOH buffer (HPLC grade, Fluka, 
Sigma Aldrich, St. Louis, MO, USA) pH 3.4) and solvent B (acetonitrile (LiChrosolv
®
, Merck, New 
York, NY, USA)) at a flow-rate of 1 mL/min. 
4.7. Determination of the Bound IS Fraction 
The protein bound fraction was calculated as follows: 
 
The ratio KD/Bm was calculated from the respective values of KD and Bm obtained from the 
experimental free and bound IS concentrations. The ratio KD/Bm served for the calculation of the 
theoretical protein bound fraction, using Equation (1). Theoretical and experimental protein bound 
fractions were compared at low toxin-albumin ratio (α = 0.1). The protein bound fractions were 
determined as follows: for the theoretical approach, α was set at 0.1; for the experimental approach, α 
was obtained from the total toxin concentration measured by HPLC and the albumin concentration 
determined using laser nephelometry (BN ProSpec, Siemens, Germany): 
 
4.8. Data Analysis 
If not differently indicated, results are presented as mean ± SD of three different donors (n = 3). The 
comparative analysis of the binding affinity and capacity in human plasma was performed by using the 
paired Student’s t-test. Differences between uremic versus healthy plasma were analyzed by applying 
the Mann-Whitney-U-test, if the results were not normally distributed, and with a one-way ANOVA 
followed by the Tukey’s post hoc test, if normally distributed. A p-value < 0.05 was considered significant. 
5. Conclusions 
Increasing the ionic strength by modification of the NaCl concentration as well as higher 
temperature are effective to reduce the protein binding affinity and, consequently, the protein bound 
fraction of the uremic toxin IS in human plasma. Dilution further decreases the protein bound fraction 
by lowering the binding capacity of the plasma proteins. As only the free toxin fraction is removed 
during hemodialysis, these measures represent interesting approaches to enhance the removal of protein 
bound uremic toxins from blood, which may be beneficial for the outcome of patients undergoing dialysis. 
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